VAUGHAN, ON and LAVAL, QC, March 22, 2022 /PRNewswire/ — Solta Medical Corporation (“Solta”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), announced that Gary Gemignani will join as Chief Financial Officer (CFO), effective March 28, 2022.
An accomplished healthcare executive with more than 35 years of experience in financial and business strategy, Mr. Gemignani has held several CFO positions in various pharmaceutical and life science companies for nearly 20 years. Earlier in his career, he held numerous global finance roles, including financial controller roles in United States and the Asia Pacific region for Novartis Pharmaceuticals, Prudential Financial and Wyeth, which followed a long tenure at Arthur Andersen.
“Gary has a well-established background in the life sciences industry, and his expertise in finance and operations makes him a welcome addition to our Solta leadership team,” said Scott A. Hirsch, Managing Director, Solta. “I have known Gary for several years, and I am confident that his global financial background is the right fit for us as we begin this new chapter for Solta and launch our IPO, subject to market conditions, approvals and disclosures. ‘other factors.’
“It’s an exciting time to join Solta, which has a strong reputation as an innovative leader in medical aesthetics, and I look forward to working with Scott and the management team during this pivotal time to company,” Mr. Gemignani said.
On Gary Gemignani
Gary Gemignani most recently he was Executive Vice President (EVP) and Chief Financial Officer of Acacia Pharma Group plc, where he led the Finance and Corporate Strategy functions. Previously, he was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from 2017 to 2019 and Chief Executive Officer and Chief Financial Officer of Biodel Inc. from 2014 to 2016. He was also a consultant for TNI Biotechnology from 2012 to 2014; as EVF and CFO of Champions Oncology Inc. from 2011 to 2013; as Executive Vice President, Chief Financial Officer and Chief Operating Officer of Coronado Biosciences from 2010 to 2011; and as Executive Vice President and Chief Financial Officer of Gentium SPA from 2006 to 2010. Earlier in his career, Mr. Gemignani held various positions of increasing importance in the financial organizations of Novartis Pharmaceuticals, Prudential Financial and Wyeth. He began his career in 1986 at Arthur Andersen & Company. Mr. Gemignani currently sits on the boards of Algorithm Sciences and Bluejay Diagnostics. He earned a bachelor’s degree in accounting from St. Peter’s College.
At February 8, 2022, Bausch Health announced that Solta has publicly filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (the “SEC”) regarding a proposed initial public offering (“IPO”) ordinary shares of Solta. The number of shares to be offered and the price range of the proposed offer have not yet been determined. Solta has applied to list its common stock on the Nasdaq Global Select Market under the symbol “SLTA”.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or territory.
Solta is one of the world’s leading aesthetic medical device companies focused on developing, manufacturing and selling innovative technologies that deliver aesthetic and therapeutic benefits. With one of the longest track records in the aesthetic medical device industry, the leading brands in their category – Thermage®, Clear + Brilliant®, Fraxel® and VASER® – are well respected and well known among aesthetic care consumers in skin and body. . Solta is headquartered in Vaughan, ON with a registered office at Bridgewater, New Jersey. For more information, visit www.solta.com and connect with us on LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) is a global company whose mission is to improve people’s lives through our healthcare products. Bausch Health develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. Bausch Health delivers on its commitments by building an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
This press release may contain forward-looking statements regarding a possible IPO or transaction involving Solta, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “has ‘intent to’, ‘plans’, ‘should’, ‘could’, ‘would’, ‘may’, ‘believes’, ‘believes’, ‘potential’, ‘target’ or ‘continues’ and variations or similar expressions, including statements regarding the timing of the completion of the IPO and the price of the common shares to be issued pursuant to the IPO.These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties. which could cause actual results to differ materially from those described in the forward-looking statements.These risks and uncertainties include, but are not limited to, the risks and uncertainties identified in the IPO Prospectus. stock Exchange ; risks relating to the transaction not being completed on time, if at all, including due to unfavorable market or other conditions or factors; risks relating to the receipt (or non-receipt) of regulatory approvals required in connection with the transaction and the timing of receipt of such approvals; the possibility that other approvals or conditions of the transaction may not be received or satisfied on a timely basis or at all; changes in the expected timing for the closing of the transaction; business disruption during or after the transaction; diversion of management time on transaction-related matters; the ability to retain members of Solta’s management team; the risks associated with the reaction of customers and other parties to such a transaction; the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties; and other events that could adversely impact the completion of the transaction, including industry or economic conditions beyond the control of Bausch Health or Solta. In particular, neither Bausch Health nor Solta can guarantee that an IPO will occur, or that such transaction or transactions will occur on the time, in the manner or on the terms provided by Bausch Health or Solta.
Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Neither Bausch Health nor Solta undertakes to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.
SOURCE Bausch Health Companies Inc.